Aarti Drugs' Q2 FY 2026-27 Quarterly Results

Result Summary

• Aarti Drugs Ltd reported a 17.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 26.9%.
• Its expenses for the quarter were up by 13.8% QoQ and 21.4% YoY.
• The net profit increased 65.1% QoQ and increased 83.3% YoY.
• The earnings per share (EPS) of Aarti Drugs Ltd stood at 9.07 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Aarti Drugs Ltd is a prominent pharmaceutical company situated in India. The company primarily focuses on manufacturing and marketing active pharmaceutical ingredients (APIs), formulations, and chemicals. Its product portfolio is diversified, covering therapeutic segments such as antibiotics, anti-inflammatory, anti-fungal, and others. As a player in the highly competitive pharmaceutical industry, Aarti Drugs has been involved in various strategic expansions and collaborations to enhance its market presence and production capabilities. Recent developments in the company might include capacity expansions or strategic alliances, although specific details are not available in the provided data.

Revenue

In the second quarter of fiscal year 2027 (Q2FY27), Aarti Drugs Ltd reported a total income of ₹828.79 crores. This reflects a quarter-over-quarter (QoQ) increase of 17.8% from ₹703.59 crores in Q1FY27, and a year-over-year (YoY) growth of 26.9% from ₹652.88 crores in Q2FY26. The growth in revenue indicates a strong performance over both the previous quarter and the same quarter last year. This substantial increase in total income highlights the company’s ability to enhance its sales or expand its market share during this period.

Profitability

The profitability of Aarti Drugs Ltd has seen a significant improvement in Q2FY27. The company posted a profit before tax of ₹109.29 crores, marking a 57.8% increase QoQ from ₹69.24 crores in Q1FY27, and an 80.9% rise YoY from ₹60.41 crores in Q2FY26. After accounting for taxes, the profit after tax stood at ₹82.77 crores, demonstrating a 65.1% growth QoQ from ₹50.13 crores and an 83.3% increase YoY from ₹45.16 crores. The earnings per share (EPS) for Q2FY27 was ₹9.07, which is up by 65.2% QoQ from ₹5.49 and 83.2% YoY from ₹4.95. These metrics highlight the company's enhanced profitability over the periods compared.

Operating Metrics

The operating expenses of Aarti Drugs Ltd in Q2FY27 amounted to ₹719.50 crores, showing a 13.8% increase QoQ from ₹632.26 crores and a 21.4% rise YoY from ₹592.47 crores. Despite the rise in expenses, the company achieved higher income and profit margins. The tax expense for Q2FY27 was ₹26.52 crores, which has increased by 38.8% QoQ from ₹19.11 crores and by 73.9% YoY from ₹15.25 crores, reflecting the higher profitability and, consequently, higher tax liabilities. The analysis of these operating metrics reveals the company’s efficient management of operational costs relative to its revenue growth.